Search

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Results for Jardiance® (empaglifozin) | BI US

Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.

Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US

BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) analysis reinforces established safety profile

Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US

Analyses show risk reductions were consistent across age groups for CV outcomes with JARDIANCE compared with placebo. View ISI, PI & Med Guide.

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

FDA accepts Jardiance sNDA for T2D in children 10 and older

The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.

Supply Chain Scholarship for Cowtribe

A supply chain course we sponsored boosted the career of Latifa Saaka

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

Jardiance® (empagliflozin) Tablets Reduce Risk of CV Death | Boehringer Ingelheim US

EMPA-REG OUTCOME® trial: New analyses show that JARDIANCE reduced the risk of CV death in adults with T2D. View ISI, PI and Med Guide.

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Pioneers who inspire: Women in livestock

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Phase III EMPA-KIDNEY trial will stop early

The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.

Partnering Days

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers